Journal of Oncology / 2020 / Article / Tab 1 / Research Article
Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer Table 1 Baseline characteristics of 65 locally advanced/metastatic gastric cancer patients.
N = 65 (%)Age, years Mean (range) 65.4 (31–85) ≧65 years 33 (50.8) <65 years 32 (49.2) Gender Male 42 (64.6) Female 23 (35.4) Tumor size <5 cm 36 (55.4) ≧5 cm 29 (44.6) Clinical T status T4 47 (72.3) T3 18 (27.7) Clinical N status N 1 10 (15.4) N 2 + N 3 55 (84.6) Vascular invasion Positive 10 (15.4) Negative 13 (20.0) ND 42 (64.6) Perineural invasion Positive 11 (16.9) Negative 12 (18.5) ND 42 (64.6) Clinical TNM stage Stage III 41 (63.1) Stage IV 24 (36.9) Tumor location Cardiac 18 (27.7) Body 18 (27.7) Antrum 31 (47.7) Diffuse (borrmann IV) 18 (27.7) Stump 3 (4.6) Histology Well-differentiated 0 Moderately differentiated 15 (23.1) Poorly differentiated 50 (76.9) Metastasis site Peritoneum carcinomatosis 8 (12.3) Liver 7 (10.8) Lung 6 (9.2) Bone 2 (3.1) Ovary 3 (4.6) Bladder 1 (1.5) Pretreatment CEA (ng/ml) ≧5 16 (24.6) <5 49 (75.4) Posttreatment CEA (ng/ml) ≧5 20 (30.8) <5 45 (69.2) TNM downstaging Yes 18 (27.7) No 47 (72.3) T downstaging Yes 17 (26.2) No 48 (73.8) N downstaging Yes 16 (24.6) No 49 (75.4) R0/R1 resection Yes 25 (38.5) No 40 (61.5) CCRT or chemotherapy CCRT 30 (46.2) Chemotherapy 35 (53.8)
ND=Not done (38 patients: unresectable tumor; 2 patients: complete response after neoadjuvant chemoradiotherapy); CEA: carcinoembryonic antigen; CCRT = concurrent chemoradiotherapy.